
27 drugs within Medicare will face penalties for having their prices raised faster than the rate of inflation.
27 drugs within Medicare will face penalties for having their prices raised faster than the rate of inflation.
Technological advances hold promise for mitigating human error in the pharmaceutical industry, especially in quality assurance/quality control, by reducing the incidence of, and risk associated with, mistakes.
A phase-appropriate analytical development strategy is crucial, especially for complex (formulated) drug substances.
This article focuses on drawing parallels between ICH Q14/Q2(R2), United States Pharmacopeia (USP) <1220>, and International Organization for Standardization/International Electrotechnical Commission (ISO/IEC) 17025:2017.
This article provides an overview of validation concept principles evolution to a life cycle risk-based approach with focus on compendial perspectives.
Quality quartets support an integrated and stable combination of commissioning and qualification and quality risk management processes.
FDA is seeking $7.2 billion to enhance food safety and advance medical product availability.
Even after an FDA advisory panel voted 14–1 in October 2022 to remove the drug, Makena manufacturer Covis Pharma continued to press for some continued access to the therapy.
Congressional leaders are investigating how pharmacy benefit managers determine health plan coverage and charges for medicines.
Any patients who have received the identified lots or have any questions regarding the recall should contact their pharmacy or immediately contact a health provider in terms of medical advice.
Advances in vaccine development are creating partnerships and stimulating clinical trials to develop new mRNA applications.
Good distribution practices ensure appropriate physical storage, distribution, and supply chain security, says Siegfried Schmitt, vice president, Technical, at Parexel.
That wave beginning to crash over PhRMA’s gunwales may well emanate from a startup mindset, rather than Big Pharma or government policy pundits.
Moderna and Merck’s investigational personalized mRNA cancer vaccine has been granted Breakthrough Therapy Designation by FDA.
Sanofi’s once-weekly replacement therapy is FDA-approved for prevention and treatment of bleeding episodes in people with hemophilia A.
GAO calls for more oversight of institutional review boards in clinical trials.
Apellis Pharmaceuticals’ Syfovre is a pegcetacoplan injection intended for the treatment of geographic atrophy secondary to age-related macular degeneration.
After years of FDA issuing guidance documents and launching programs to encourage sponsors to seek broader representation in clinical trials, policy makers have added a “stick” to the process.
Biden outlined a host of priorities for improving health care and building the economy during State of the Union address.
A realignment of the Office of Regulatory Affairs would create a focus on “critical activities” for ensuring the safety of foods and other regulated products, including drugs, biologics, and medical devices.
Variability instills consistency in advanced therapy medicinal products.
A Congressional probe of FDA’s approval of Alzheimer’s treatment targets the agency’s interactions with drug manufacturers.
The restraint to not target solely the major disease groups has provided good proportion and balance for our industry.
FDA will restart in-person, face-to-face meetings with industry sponsors beginning Feb. 13, 2023, after a shift to all-virtual meetings during the pandemic.
Big data is a natural for pharmaceutical industry players that have not already embraced it.